Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate Resistance Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01468532
What this trial is testing

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Barbara Ann Karmanos Cancer Institute 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06836726
What this trial is testing

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
University Health Network, Toronto 35
Testing effectiveness (Phase 2)Ended earlyNCT01717898
What this trial is testing

Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

Who this might be right for
Castrate-resistant Prostate Cancer
Charles Ryan 6
Not applicableActive Not RecruitingNCT02730338
What this trial is testing

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Who this might be right for
Metastatic Prostate Cancer
Movember Foundation 866
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Testing effectiveness (Phase 2)Study completedNCT01360840
What this trial is testing

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
EMD Serono 180
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Testing effectiveness (Phase 2)WithdrawnNCT01481233
What this trial is testing

Oral Colchicine in Men With Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Milton S. Hershey Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT01267266
What this trial is testing

Saracatinib in Treating Patients With Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 31
Not applicableUnknownNCT01168141
What this trial is testing

Window Study of ZD4054 in Metastatic Prostate Cancer

Who this might be right for
Prostate CancerMetastasis
The Christie NHS Foundation Trust 30
Testing effectiveness (Phase 2)Study completedNCT00831792
What this trial is testing

TKI258 in Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 46
Not applicableStudy completedNCT00578409
What this trial is testing

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 758
Testing effectiveness (Phase 2)Ended earlyNCT03690141
What this trial is testing

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Who this might be right for
Castrate-resistant Prostate Cancer (CRPC)
Effector Therapeutics 16
Testing effectiveness (Phase 2)Study completedNCT01683994
What this trial is testing

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
National Cancer Institute (NCI) 49
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Testing effectiveness (Phase 2)Study completedNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Not applicableStudy completedNCT02008058
What this trial is testing

Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer
UNC Lineberger Comprehensive Cancer Center 213
Testing effectiveness (Phase 2)Ended earlyNCT00515112
What this trial is testing

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Chicago 6
Early research (Phase 1)Active Not RecruitingNCT03089203
What this trial is testing

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Pennsylvania 23
Testing effectiveness (Phase 2)Ended earlyNCT03572478
What this trial is testing

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Who this might be right for
Prostate CancerEndometrial Cancer
University of Chicago 12
Next Page